Hypertonic saline is effective in the prevention and treatment of mucus obstruction, but not airway inflammation, in mice with chronic obstructive lung disease

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 3, 2013, Pages 410-417

  Graeber, Simon Y ^a   Zhou Suckow, Zhe ^a   Schatterny, Jolanthe ^a   Hirtz, Stephanie ^a   Boucher, Richard C ^b   Mall, Marcus A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Airway surface liquid; Chronic obstructive pulmonary disease; Cystic fibrosis; Inflammation; Mucus

Indexed keywords

BETA EPITHELIAL SODIUM CHANNEL; CHEMOATTRACTANT; SODIUM CHANNEL; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EFFICACY; IN VIVO STUDY; KERATINOCYTE; MORTALITY; MOUSE; NEUTROPHIL; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; SURFACE PROPERTY;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; CHEMOTAXIS; DISEASE MODELS, ANIMAL; EPITHELIAL SODIUM CHANNELS; GENE EXPRESSION; INFLAMMATION; KERATINOCYTES; LUNG; MICE; MUCUS; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SALINE SOLUTION, HYPERTONIC;

EID: 84883480967     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0050OC     Document Type: Article

References (50)

1. Knowles MR, Stutts MJ, Spock A, Fischer N, Gatzy JT, Boucher RC. Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 1983;221:1067-1070. (Pubitemid 13041960)
2. + conductance is reduced by cystic fibrosis transmembrane conductance in normal but not in cystic fibrosis airways. J Clin Invest 1998;102:15-21.
3. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95:1005-1015. (Pubitemid 29019052)
4. Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 2007;58:157-170. (Pubitemid 46706507)
5. Mall MA. Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models. J Aerosol Med Pulm Drug Deliv 2008;21:13-24.
6. Mall M, Boucher RC. Pathogenesis of pulmonary disease in cystic fibrosis. In: Bush A, Alton E, Davies J, Griesenbach U, Jaffe A, editors. Cystic fibrosis in the 21st century. Basel: Karger; 2006. pp. 116-121. (Pubitemid 41417545)
7. Button B, Cai LH, Ehre C, Kesimer M, Hill DB, Sheehan JK, Boucher RC, Rubinstein M. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 2012;337:937-941.
8. Anagnostopoulou P, Riederer B, Duerr J, Michel S, Binia A, Agrawal R, Liu X, Kalitzki K, Xiao F, Chen M, et al. SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation. J Clin Invest 2012;122:3629-3634.
9. Mall MA, Button B, Johannesson B, Zhou Z, Livraghi A, Caldwell RA, Schubert SC, Schultz C, O'Neal WK, Pradervand S, et al. Airway surface liquid volume regulation determines different airway phenotypes in liddle compared with betaENaC-overexpressing mice. J Biol Chem 2010;285:26945-26955.
10. Johannesson B, Hirtz S, Schatterny J, Schultz C, Mall MA. CFTR regulates early pathogenesis of chronic obstructive lung disease in βENaC- overexpressing mice. PLoS One 2012;7:e44059.
11. Voynow JA, Gendler SJ, Rose MC. Regulation of mucin genes in chronic inflammatory airway diseases. Am J Respir Cell Mol Biol 2006;34:661-665. (Pubitemid 43825329)
12. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med 2010;363:2233-2247.
13. Tarran R, Grubb BR, Parsons D, Picher M, Hirsh AJ, Davis CW, Boucher RC. The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell 2001;8:149-158. (Pubitemid 32772913)
14. Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, Bautovich GJ, King M, Bye PT. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997;52:900-903. (Pubitemid 27473934)
15. Goralski JL, Boucher RC, Button B. Osmolytes and ion transport modulators: new strategies for airway surface rehydration. Curr Opin Pharmacol 2010;10:294-299.
16. Reeves EP, Molloy K, Pohl K, McElvaney NG. Hypertonic saline in treatment of pulmonary disease in cystic fibrosis. ScientificWorldJournal 2012;2012:465230.
17. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-250. (Pubitemid 43113029)
18. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240. (Pubitemid 43113028)
19. Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, McNamara S, Johnson R, Kronmal R, Davis SD; ISIS Study Group. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 2012;307:2269-2277.
20. Subbarao P, Stanojevic S, Brown M, Jensen R, McDonald N, Gent K, Davis SD, Rosenfeld M, Gustafsson P, Ratjen F. Effect of hypertonic saline on lung clearance index in infants and preschool children with CF: a pilot study [abstract]. Pediatr Pulmonol Suppl 2012;35:301-302.
21. Hashimoto S, Matsumoto K, Gon Y, Nakayama T, Takeshita I, Horie T. Hyperosmolarity-induced interleukin-8 expression in human bronchial epithelial cells through p38 mitogen-activated protein kinase. Am J Respir Crit Care Med 1999;159:634-640. (Pubitemid 29084892)
22. Tabary O, Escotte S, Couetil JP, Hubert D, Dusser D, Puchelle E, Jacquot J. High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the I kappa B kinase alpha pathway in response to extracellular NaCl content. J Immunol 2000;164:3377-3384. (Pubitemid 30149004)
23. Silber G, Proud D, Warner J, Naclerio R, Kagey-Sobotka A, Lichtenstein L, Eggleston P. In vivo release of inflammatory mediators by hyperosmolar solutions. Am Rev Respir Dis 1988;137:606-612. (Pubitemid 18081637)
24. Nightingale JA, Rogers DF, Barnes PJ. Effect of repeated sputum induction on cell counts in normal volunteers. Thorax 1998;53:87-90. (Pubitemid 28212131)
25. van der Vaart H, Postma DS, Timens W, Kauffman HF, Hylkema MN, Ten Hacken NH. Repeated sputum inductions induce a transient neutrophilic and eosinophilic response. Chest 2006;130:1157-1164. (Pubitemid 44583748)
26. + absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004;10:487-493.
27. + channel-overexpressing mice. Am J Respir Crit Care Med 2008;177:730-742.
28. Wielpütz MO, Eichinger M, Zhou Z, Leotta K, Hirtz S, Bartling SH, Semmler W, Kauczor HU, Puderbach M, Mall MA. In vivo monitoring of cystic fibrosis-like lung disease in mice by volumetric computed tomography. Eur Respir J 2011;38:1060-1070.
29. Zhou Z, Graeber SY, Schatterny J, Hirtz S, Mall MA. Preclinical evaluation of preventive hypertonic saline therapy for cystic fibrosis-like lung disease in mice [abstract]. Pediatr Pulmonol Suppl 2010;33:304.
30. Zhou Z, Treis D, Schubert SC, Harm M, Schatterny J, Hirtz S, Duerr J, Boucher RC, Mall MA. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in βENaC-overexpressing mice. Am J Respir Crit Care Med 2008;178:1245-1256.
31. Reeves EP, Williamson M, O'Neill SJ, Greally P, McElvaney NG. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med 2011;183:1517-1523.
32. Livraghi-Butrico A, Kelly EJ, Klem ER, Dang H, Wolfgang MC, Boucher RC, Randell SH, O'Neal WK. Mucus clearance, MyD88-dependent and MyD88-independent immunity modulate lung susceptibility to spontaneous bacterial infection and inflammation. Mucosal Immunol 2012;5:397-408.
33. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653. (Pubitemid 38787999)
34. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME; the Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642. (Pubitemid 24276863)
35. Aitken ML, Bellon G, De Boeck K, Flume PA, Fox HG, Geller DE, Haarman EG, Hebestreit HU, Lapey A, Schou IM, et al.; CF302 Investigators. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012;185:645-652.
36. Stick SM, Sly PD. Exciting new clinical trials in cystic fibrosis: infants need not apply. Am J Respir Crit Care Med 2011;183:1577-1578.
37. Sly PD, Brennan S, Gangell C, de Klerk N, Murray C, Mott L, Stick SM, Robinson PJ, Robertson CF, Ranganathan SC; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009;180:146-152.
38. Stick SM, Brennan S, Murray C, Douglas T, von Ungern-Sternberg BS, Garratt LW, Gangell CL, De Klerk N, Linnane B, Ranganathan S, et al.; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF). Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 2009;155:623-628, e1.
39. Hoo AF, Thia LP, Nguyen TT, Bush A, Chudleigh J, Lum S, Ahmed D, Balfour Lynn I, Carr SB, Chavasse RJ, et al.; London Cystic Fibrosis Collaboration. Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening. Thorax 2012;67:874-881.
40. Belessis Y, Dixon B, Hawkins G, Pereira J, Peat J, MacDonald R, Field P, Numa A, Morton J, Lui K, et al. Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index. Am J Respir Crit Care Med 2012;185:862-873.
41. Rosenfeld M, Davis S, Brumback L, Daniel S, Rowbotham R, Johnson R, McNamara S, Jensen R, Barlow C, Ratjen F. Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety. Pediatr Pulmonol 2011;46:666-671.
42. Davis SD, Brody AS, Emond MJ, Brumback LC, Rosenfeld M. Endpoints for clinical trials in young children with cystic fibrosis. Proc Am Thorac Soc 2007;4:418-430. (Pubitemid 47333916)
43. Eichinger M, Optazaite DE, Kopp-Schneider A, Hintze C, Biederer J, Niemann A, Mall MA, Wielpütz MO, Kauczor HU, Puderbach M. Morphologic and functional scoring of cystic fibrosis lung disease using MRI. Eur J Radiol 2012;81:1321-1329.
44. Dickey BF. Biochemistry: walking on solid ground. Science 2012;337:924-925.
45. Evans CM, Kim K, Tuvim MJ, Dickey BF. Mucus hypersecretion in asthma: causes and effects. Curr Opin Pulm Med 2009;15:4-11.
46. Anagnostopoulou P, Dai L, Schatterny J, Hirtz S, Duerr J, Mall MA. Allergic airway inflammation induces a pro-secretory epithelial ion transport phenotype in mice. Eur Respir J 2010;36:1436-1447.
47. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev 2008;(4):CD006458.
48. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011;105:1831-1835.
49. Patel H, Platt R, Lozano JM, Wang EE. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev 2004;(3):CD004878.
50. Gadomski AM, Brower M. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev 2010;(12):CD001266.